Insider Selling: Vericel Co. (NASDAQ:VCEL) Insider Sells 3,908 Shares of Stock

Vericel Co. (NASDAQ:VCEL) insider Jonathan Siegal sold 3,908 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the completion of the sale, the insider now owns 1,206 shares of the company’s stock, valued at $74,759.94. This represents a 76.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vericel Trading Up 0.5 %

Shares of Vericel stock traded up $0.27 during trading on Thursday, reaching $59.25. The stock had a trading volume of 269,823 shares, compared to its average volume of 437,838. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 987.66 and a beta of 1.72. The stock has a fifty day moving average price of $57.66 and a two-hundred day moving average price of $50.75. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $61.99.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. On average, equities analysts forecast that Vericel Co. will post 0.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. International Assets Investment Management LLC boosted its stake in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Vericel in the third quarter valued at approximately $92,000. Finally, Geneos Wealth Management Inc. increased its position in shares of Vericel by 826.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,240 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial upped their price objective on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. BTIG Research lifted their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, Stephens restated an “overweight” rating and issued a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average price target of $62.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.